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Abstract
Background: Interim analysis of accumulating trial data is important to protect participant safety
during randomized controlled trials (RCTs). Data Monitoring Committees (DMCs) often
undertake such analyses, but their widening role may lead to extended use of interim analysis or
recommendations that could potentially bias trial results.
Methods: Systematic search of eight major publications: Annals of Internal Medicine, BMJ, Circulation,
CID, JAMA, JCO, Lancet and NEJM, including all randomised controlled trials (RCTs) between June
2000 and May 2005 to identify RCTs that reported use of interim analysis, with or without DMC
involvement. Recommendations made by the DMC or based on interim analysis were identified and
potential sources of bias assessed. Independent double data extraction was performed on all
included trials.
Results: We identified 1772 RCTs, of which 470 (27%; 470/1772) reported the use of a DMC and
a further 116 (7%; 116/1772) trials reported some form of interim analysis without explicit mention
of a DMC. There were 28 trials (24 with a formal DMC), randomizing a total of 79396 participants,
identified as recommending changes to the trial that may have lead to biased results. In most of
these, some form of sample size re-estimation was recommended with four trials also reporting
changes to trial endpoints. The review relied on information reported in the primary publications
and methods papers relating to the trials, higher rates of use may have occurred but not been
reported.
Conclusion: The reported use of interim analysis and DMCs in clinical trials has been increasing
in recent years. It is reassuring that in most cases recommendations were made in the interest of
participant safety. However, in practice, recommendations that may lead to potentially biased trial
results are being made.
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Background
Randomized controlled trials (RCTs) provide essential
evidence on the efficacy and safety of medical interven-
tions. Monitoring of accruing trial data is important to
ensure participant safety [1,2]. The International Confer-
ence on Harmonisation (ICH) recommends that such
analyses be conducted by individuals with no vested inter-
est in the outcome of the trial where possible, particularly
in large confirmatory Phase III trials [3].
When formalized, this role is commonly performed by a
multi-disciplinary group of specialist, often referred to as
a Data Monitoring Committee (DMC), which makes rec-
ommendations to those in charge of the overall manage-
ment of the trial, often referred to as the Trial Steering
Committee (TSC). Also, interim analyses should prefera-
bly be pre-specified in the trial protocol to minimize bias
from unplanned analyses [1]. DMC recommendations
typically include either: continuing the trial as planned;
stopping early for hazard; stopping because efficacy is
unequivocally established; or stopping because continu-
ing the trial is futile [4].
Whilst it is widely accepted that the primary role of the
DMC is to protect participant safety, several other roles of
the DMC have been suggested, including recommending
protocol amendments based on interim analysis [5]. Such
amendments can lead to potentially biased results and
damage the integrity of the trial as highlighted in recent
FDA guidance:
"Many kinds of trial modifications (e.g. changing endpoints,
changing or adding to pre-specified analysis subgroups) could,
if made with knowledge of trial results, have significant effects
on type I error and interpretation of final results. If it is per-
ceived that emerging results could have influenced these types
of interim protocol changes, the credibility of the trial may be
severely damaged. In general, to minimize the potential for
bias, the trial leadership, which is insulated from knowledge of
the interim data, rather than the DMC, should be responsible
for proposing potential changes other than those driven by safety
considerations." [1]
It is unclear to what extent protocol modifications have
been made in trials based on interim analyses, and more
specifically as a result of recommendations by DMCs.
Therefore, we systematically reviewed the reported use of
interim analyses and DMCs to identify trials in which
interim data have been used for reasons other than to
make one of the recommendation described above, refer-
ring to these occurrences as "extended use of interim anal-
ysis" or "extended recommendations by DMCs" for the
purposes of discussion here. Patterns of interim analysis
use, roles assumed by the DMCs, and potential bias-
related and ethical issues arising from such actions are dis-
cussed.
Methods
Data Sources and Searches
A search strategy that allowed for the identification of rel-
evant case studies with extended recommendations based
on interim analysis or by DMC was used. We conducted a
systematic search of eight journals, Annals of Internal Med-
icine, BMJ, Circulation, Clinical Infectious Diseases (CID),
JAMA, the Journal of Clinical Oncology (JCO), Lancet and the
New England Journal of Medicine (NEJM), to identify RCTs
reporting the use of interim analysis with or without spec-
ification of a DMC, between June 2000 and June 2005.
These journals were selected to include major generalist
and specialist medical journals.
The title and abstract of every citation in the full-text jour-
nal content databases published within the time period
searched was checked to identify whether it was indeed a
main results paper of a RCT. Subsequently, the full-text of
all RCT articles in the Portable Document Format (PDF)
was scanned using a set of keywords. These keywords were
found to be most likely to appear in relevant sections of
the articles during a piloting exercise. This included
interim, monitor, early, stop, terminate, survival, death and
mortality.
Study Selection and Data Extraction
Identified RCTs were classified according to therapeutic
area and assessed (by P.T.) to determine: whether mortal-
ity was listed as an endpoint (primary, secondary or part
of a composite endpoint), whether interim analysis was
reported, and whether a DMC was reported. Various
names referring to DMCs were considered.
All trials reporting interim analysis were categorized,
based on trial progress or outcome and therefore classified
as either 'Continued to or Extended beyond planned con-
clusion', 'Early stop for benefit', 'Early stop for harm',
'Stopped for futility' or 'Early stop for other reasons'. Next,
using information in the results and where available
design articles or trial protocols, trials were assessed to
determine whether other actions of the DMC or release of
interim data could have led to "extended recommenda-
tions" and whether these had the potential to introduce
bias or complicate the interpretation of the results.
Independent double data extraction (M.C., P.T.) was per-
formed on all trials considered to have "extended" use of
interim data or DMC recommendations. A non-linear
model accounting for journal was used to estimate
whether the rate of DMC use increased by year.BMC Medical Research Methodology 2008, 8:12 http://www.biomedcentral.com/1471-2288/8/12
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Results
Reported use of Interim analysis and DMCs
In total, 1772 trials were identified, of which 470 (27%;
470/1772) reported the use of interim analysis and speci-
fied use of a DMC (this count includes trials that reported
use of a DMC and interim monitoring plans, but did not
report implementation of the analysis during the course
of the trial). A further 116 trials reported some form of
interim analysis without explicit mention of a DMC, giv-
ing a total of 586 (33%; 586/1772) trials that reported the
use of interim analysis. There was a higher rate of reported
use in trials that included mortality as an endpoint (54%;
410/764). The Lancet published most trials (352/1682;
21%), with JCO reporting the most mortality trials (233/
285; 82%).
The proportion of trial reports describing the use of
interim analysis, with or without specification of a DMC,
ranged from 10% (21/209) in the BMJ to 58% (160/274)
in the NEJM. The reported use in mortality trials also var-
ied with the JCO reporting interim analysis in 35% (81/
233) of such trials compared to over 70% in JAMA (44/
69),NEJM (112/149) and the Lancet (94/130).
The reported use within specific therapeutic areas ranged
from 30% (22/71) in Pediatrics to 47% (20/43) in Obstet-
rics and Gynecology (Table 1).
There was a significant (P < .001) rise in the number of tri-
als reporting use of interim analysis over the period
reviewed, with 86 trials reporting use between June 2000
to May 2001, and 151 trials for June 2004 to May 2005.
Recommendations based on interim analysis or made by 
DMCs
Of the 586 trials that reported use of interim analysis, with
or without specification of a DMC, 444 trials (76%; 444/
586) continued as planned, 75 trials (13%; 75/586)
stopped early because of benefit or harm to study partici-
pants, 26 (4%; 26/586) stopped early for other reasons
and 28 (5%; 28/586) were stopped for futility (Table 2).
A total of 74 trial reports (13%; 74/586) had "extended"
use or recommendations and were further examined (Fig-
ure 1, Table 2). Of these, 46 (8%; 46/586) trials included
recommendations or amendments aiming to ensure par-
ticipant safety, which is unlikely to have introduced bias,
and therefore did not complicate the interpretation of the
results. For example, the expansion of exclusion criteria to
ensure that children with unrecognized HIV infections
were not included was recommended by the DMC subse-
quent to interim analysis in a trial comparing the use of
oral amoxicillin with injectable penicillin for severe pneu-
monia [6].
There were 28 trials (5%; 28/586), randomizing 79396
participants, identified as having extended recommenda-
tions based on interim analysis with the potential to intro-
duce bias to trial results, or to lead to problems with
interpretation. Most were either cardiovascular or oncol-
ogy trials and the extended use or recommendations
noted in these trials are detailed in Additional file 1.
Among these, 24 trials (randomizing a total of 75838 par-
ticipants) reported use of DMCs while there was reported
use of interim analysis without specific mention of DMCs
in the remaining four studies. Nine of these 28 trials were
regulatory trials (Figure 1).
Trials identified as having extended use of interim data or 
DMC recommendations with the potential to introduce 
bias
Sample size re-estimation (SSR)
In 27 of the 28 trials that were judged to be open to bias,
some form of SSR was recommended subsequent to the
review of interim data. The recommendation for SSR was
implemented as a protocol amendment in 26 of these (see
Additional file 1).
Table 1: Breakdown of retrieved trials by Therapeutic Area
Therapeutic Area Total number of trials 
retrieved in search
Trials reporting interim 
analysis (with or without 
specification of a DMC)
Trials identified as having 
extended use of interim data or 
DMC recommendations with the 
potential to introduce bias
Total (N) 1772 586 28
Cardiovascular Disease (CVD) 494 209 11
Oncology (ONC) 387 136 11
Infection (INF) 271 93 2
Pediatrics (PED) 71 22 0
Obstetrics & Gynecology 
(OBGYN)
43 20 2
Neurology (NEURO) 50 17 1
Other 456 89 1BMC Medical Research Methodology 2008, 8:12 http://www.biomedcentral.com/1471-2288/8/12
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Several publications reported that interim trends observed
in individual treatment arms were used as the basis for a
SSR recommendation [7-12]. For instance, the Public-
Access Defibrillation and Survival after Out-Of-Hospital
Cardiac Arrest (PAD) trial [12], assessed whether training
laypersons to use automated external defibrillators in
addition to cardiopulmonary resuscitation (CPR)
increased survival from out of hospital cardiac arrest. The
report states that '(T)he observed numbers of arrests were
substantially lower than anticipated from the pre-rand-
omization unit-enrolment data; however, the survival rate
in the CPR-only units was higher than anticipated. After
the interim analysis, information regarding the frequency
of cardiac arrests and the survival rate in the CPR-only
units was used to extend the data-collection period by six
months to maintain the specified power level'.
Table 2: Overall classification of RCTs reporting interim analysis or DMC use based on trial progress
Trial Progress Trials reporting interim 
analysis (with or without 
specification of a DMC)
Trials identified as having 
extended use of interim data 
or DMC recommendations
Trials identified as having extended 
use of interim data or DMC 
recommendations with the 
potential to introduce bias
Total (N) 586 74 28
Continued to or Extended beyond 
planned conclusion
457 55 26
Early stop for benefit 53 7 1
Early stop for harm 22 3 0
Stopped for futility 28 7 0
Early stop for other reasons 26 2 1
Identification of Randomized Controlled Trials retrieved during Systematic Search Figure 1
Identification of Randomized Controlled Trials retrieved during Systematic Search.
28 RCTs identified as having "extended use" of interim analysis
or "extended recommendations" made by DMCs with the potential to introduce bias
(24 specify use of a DMC)
(9 were regulatory trials)
74 RCTs identified as having "extended use" of interim analysis
 or "extended recommendations" made by DMCs
586 RCTs report use of interim analysis or a DMC
(468 specify use of a DMC)
(410 report mortality as an endpoint)
1772 RCTs Retrieved
(764 report mortality as an endpoint)BMC Medical Research Methodology 2008, 8:12 http://www.biomedcentral.com/1471-2288/8/12
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There also were examples where the authors were specific
that the SSR recommendation was made subsequent to
interim analysis or by the DMC based on overall rates [13-
18]. In six trials where SSR was recommended, the authors
make reference to the use of masked interim data
[13,15,16,19-21]. In these cases, data reviewed by the
DMC did not identify which treatment was associated
with each group.
Trial endpoint amendments
Two trials reported changes to the primary endpoint
based on interim analysis [9,15], one introduced an addi-
tional (secondary) endpoint [22] and one dropped an
endpoint [23] subsequent to interim analyses.
CAPRICORN (CArvedilol PostinfaRct survIval COntRol
in LV dysfunctioN) investigated the effects of carvedilol, a
beta-blocker, in patients with left ventricular dysfunction
following myocardial infarction [15]. The original pri-
mary endpoint in the protocol was all-cause mortality.
However, while the study was ongoing, the primary end-
point was amended by the TSC by dividing the available
statistical power (P = 0.05) between a new composite end-
point (all-cause mortality or cardiovascular hospital
admissions, P = 0.045) and the original primary endpoint
(all-cause mortality, P = 0.005). The results publication
for this trial states that the TSC took the decision because
the DMC 'noted that overall mortality was lower than had
been predicted and that the study could not be completed
with the sample size and power originally planned.'
In a trial in chronic lymphatic leukemia that compared
fludarabine with chlorambucil, the initial sample size was
based on a comparison of the rates of complete remission
[9]. However, there was a post-hoc change of the primary
endpoint to progression-free survival, a time-to-event
measure. The reason given for this change was 'that the
response rate in the chlorambucil group was significantly
lower than the rates in the other two groups,' as observed
during an interim analysis.
Discussion
The use of interim analysis and DMCs in clinical trials
reported in major journals has increased in recent years. A
possible explanation for the variation in the rate of
reported use of interim analysis or DMCs among the jour-
nals searched (Table 1) is the nature of trials published
and the methods of reporting in the publication. For
instance, the high rate among trials published in the
NEJM is probably because it often attracts landmark clin-
ical trials that may have a higher likelihood of having used
interim analysis and it was easier to spot relevant informa-
tion due to the more structured format used by the jour-
nal.
Also of note is the large proportion of trials that included
mortality as an endpoint in the JCO but comparatively
low rate of interim analysis and DMC use among the trials
published in that journal, possibly indicating a need for
increased uptake or improved reporting in the oncology
sector.
The majority of recommendations based on interim anal-
ysis or by DMCs were either to continue the trial as
planned or to terminate early. This is reassuring as DMCs
can be seen to be fulfilling their primary role of protecting
participant safety. Our review also shows that, in practice,
extended use of interim analysis or extended DMC recom-
mendations are being made, some of which could poten-
tially introduce bias and produce disputable results.
Limitations
A limitation of our review is that we relied on information
reported in the primary publications and methods papers
relating to the trials, therefore trial publications that did
not acknowledge the use of interim analysis or DMC and
related protocol amendments might not have been iden-
tified. Furthermore, many trials that are terminated early
or amended during the course of the trial may never be
published.
Sample size re-estimation (SSR) based on interim analysis 
or made by DMCs as a source of bias
The amendments identified were mostly sample size re-
estimations due to insufficient accrual of participants or
events. Power calculations are made based on assump-
tions that may not be reflected in the actual experience of
a trial [24]. SSR is typically an attempt to ensure that a
study's objective is accomplished with adequate power.
SSR may also be necessary due to safety considerations,
for example when a comparison in the trial is dropped for
safety reasons or when new data from other sources
becomes available during the progress of a trial.
A SSR made by the TSC based on overall event rates, with-
out knowledge of the rates of events in specific groups, is
not contentious and may be considered good practice.
However, a recommendation for SSR made with knowl-
edge of interim data introduces bias to the trial. For exam-
ple, if SSR is undertaken based on a comparison of event
rates observed during an interim analysis or if an SSR is
conducted because of a lower than expected event rate in
the control group. The latter introduces bias because rates
in one group are integral to the result of the difference
between the groups; this is a special case of regression to
the mean [25].
In PAD [12], the CPR-only units formed the control
group, and making changes to the protocol based on end-BMC Medical Research Methodology 2008, 8:12 http://www.biomedcentral.com/1471-2288/8/12
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point data from this group clearly has the potential to
introduce bias.
In the trials where SSR was performed subsequent to
interim analysis based on overall rates or the review of
masked data, it would seem that the investigators were on
the whole attempting to be explicit that the SSR recom-
mendation was made without introducing bias. However,
whether in all these cases the DMC were truly blind to
treatment allocation is debatable since in the former,
DMCs often also have access to treatment arm-specific
rates and in the latter, differences in adverse events or
trends in data may have inadvertently led to unmasking.
A trial examining whether low-dose dopamine attenuates
renal injury as compared to placebo, where masking was
implemented during the interim analysis [20], provides
an example of the difficulties with reviewing masked data,
since as the trialists described: 'there is concern about the
potential adverse effects of low-dose dopamine on pitui-
tary function, T-cell responsiveness, and gastrointestinal
oxygenation'. These adverse events would not occur with
any discernable frequency in the placebo arm, and would
unmask a DMC with knowledge of them.
Trial endpoint amendments based on interim analysis or 
made by DMCs as a source of bias
The primary endpoint should be the variable capable of pro-
viding the most clinically relevant and convincing evidence
directly related to the primary objective of the trial [26].
Changing the primary endpoint of a study in the knowl-
edge of the interim results is analogous to changing a bet
to the winning horse part way through a race, introduces
bias and leads to complications with interpretation of the
final results.
In the cases where changes were made to the primary end-
point [9,15], it appears that these may have been attempts
to achieve a positive result. In CAPRICORN, the introduc-
tion of a composite co-primary outcome subsequent to
review of interim data can be seen as an attempt to achieve
a positive trial by using a composite endpoint which
would have a higher likelihood of accruing events. The
original primary endpoint (all-cause mortality) achieved a
P-value of 0.03 (i.e. substantially larger than the 0.005
subsequently allocated to it) whilst the composite end-
point of all-cause mortality and cardiovascular hospital
admissions (new co-primary outcome) had a P-value of
0.30. Therefore, CAPRICORN should be considered a
neutral trial as neither of the co-primary endpoints
achieved statistical significance. Had the original primary
endpoint of all-cause mortality been maintained, it would
have resulted in a modestly statistically significant result
and consequently CAPRICORN would have been consid-
ered a positive trial.
In the leukemia trial [9], multiple amendments, most
notably amending the primary endpoint, were made sub-
sequent to interim analysis with knowledge of treatment-
arm specific rates in an apparent attempt to increase the
number of events accrued and achieve a successful trial,
but a substantial bias was introduced. The reporting in
this trial also highlights the need for clarity when commu-
nicating final results subsequent to protocol amend-
ments. The result of the original primary endpoint was
found to be statistically significant and the manner in
which the results of the trial were then reported in the
publication obfuscates the endpoint amendments.
Indeed, in the results section, the original primary end-
point was referred to first in the text.
Conclusion
Our review of published trials indicates that the reporting
of DMCs and interim analyses use in major journals has
increased in recent years. Many trials, including those
with mortality as an endpoint, did not appear to have any
formal interim analysis, which is inadequate if we are to
protect participant safety. In the majority of cases, recom-
mendations were made based on interim analysis in the
interest of participant safety and it is reassuring that there
was only a small proportion of trials where extended use
of interim analysis or recommendations made by the
DMC had the potential to introduce bias.
However, these trials involved nearly eighty thousand par-
ticipants and most had formal DMCs. Many trials that
stop early may never be published or are published in rel-
atively obscure journals [27]. Thus, the trials identified
here are probably a subset of a larger group of trials that
have even less adequately reported changes in design.
Empirical evidence has shown that trialists can attempt to
achieve a positive trial using multiple strategies and this is
a very real concern [28]. This review adds to these con-
cerns by highlighting how interim data can be used to
influence the results of a trial. There is clearly a need to
ensure that interim data are not misused to this end. The
role of DMCs, with their privileged access to interim data,
must be carefully considered if bias is to be avoided.
Competing interests
PT and MC have received research funding and consul-
tancy fees from the pharmaceutical and medical device
industry. JH and NF have received funding from a range of
sources including the pharmaceutical industry, research
charities and governmental bodies to undertake a number
of roles in the design, conduct and interpretation of rand-
omized trials.BMC Medical Research Methodology 2008, 8:12 http://www.biomedcentral.com/1471-2288/8/12
Page 7 of 8
(page number not for citation purposes)
Authors' contributions
PT conducted the systematic literature review, selection
and categorization of cases, data extraction, data analysis,
writing of the manuscript, and is guarantor. MC con-
ducted data extraction, data analysis, and writing of the
manuscript. NF contributed to the data extraction, data
analysis and writing of the manuscript. JH contributed to
the development of the manuscript.
Additional material
References
1. U.S. Department of Health and Human Services: Guidance for Clin-
ical Trial Sponsors: Establishment and Operation of Clinical
Trial Data Monitoring Committee.  2006 [http://www.fda.gov/
cber/gdlns/clintrialdmc.pdf].
2. European Medicines Agency (Committee for Medicinal Products for
Human Use): Guideline on Data Monitoring Committees.
2005 [http://www.emea.europa.eu/pdfs/human/ewp/587203en.pdf].
3. International Conference on Harmonisation Of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH)
Steering Committee: ICH Harmonised Tripartite Guidelines:
Statistical Principles For Clinical Trials (E9). ICH.  1998 [http:/
/www.ich.org/LOB/media/MEDIA485.pdf].
4. Ellenberg SS, Fleming TR, DeMets DL: Data Monitoring Committees
Committees in Clinical Trials: A Practical Perspective Chichester: John
Wiley; 2002. 
5. Sydes MR, Spiegelhalter DJ, Altman DG, Babiker AB, Parmar MKB, for
the DAMOCLES Group: Systematic qualitative review of the
literature on data monitoring committees for randomized
controlled trials.  Clinical Trials 2004, 1:60-79.
6. Addo-Yobo E, Chisaka N, Hassan M, Hibberd P, Lozano JM, Jeena P,
MacLeod WB, Maulen I, Patel A, Qazi S: Oral amoxicillin versus
injectable penicillin for severe pneumonia in children aged 3
to 59 months: a randomised multicentre equivalency study.
The Lancet 2004, 364(9440):1141-1148.
7. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappen-
berger L, Tavazzi L, the Cardiac Resynchronization-Heart Failure
(CARE-HF) Study Investigators: The Effect of Cardiac Resyn-
chronization on Morbidity and Mortality in Heart Failure.  N
Engl J Med 2005, 352:1539-1549.
8. The ICON and AGO Collaborators: Paclitaxel plus platinum-
based chemotherapy versus conventional platinum-based
chemotherapy in women with relapsed ovarian cancer: the
ICON4/AGO-OVAR-2.2 trial.  The Lancet 2003, 361:2099-2106.
9. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L,
Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludara-
bine Compared with Chlorambucil as Primary Therapy for
Chronic Lymphocytic Leukemia.  N Engl J Med 2000,
343:1750-1757.
10. To MS, Alfirevic Z, Heath VC, Cicero S, Cacho AM, Williamson PR,
Nicolaides KH: Cervical cerclage for prevention of preterm
delivery in woman with short cervix: randomised controlled
trial.  The Lancet 2004, 363:1849-1853.
11. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW,
McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ:
Adjuvant Immunotherapy of Patients With High-Risk
Melanoma Using Vaccinia Viral Lysates of Melanoma:
Results of a Randomized Trial.  J Clin Oncol 2002, 20:4181-4190.
12. The Public Access Defibrillation Trial Investigators: Public-Access
Defibrillation and Survival after Out-of-Hospital Cardiac
Arrest.  N Engl J Med 2004, 351:637-646.
13. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman
M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J,
Adami HO, Johansson JE, Norlen BJ: A Randomized Trial Com-
paring Radical Prostatectomy with Watchful Waiting in
Early Prostate Cancer.  N Engl J Med 2002, 347:781-789.
14. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, Macdon-
ald KS, Maclean IW, Bwayo JJ, Temmerman M, Ronald AR, Moses S:
Monthly Antibiotic Chemoprophylaxis and Incidence of Sex-
ually Transmitted Infections and HIV-1 Infection in Kenyan
Sex Workers: A Randomized Controlled Trial.  JAMA 2004,
291:2555-2562.
15. The CAPRICORN Investigators: Effect of carvedilol on outcome
after myocardial infarction in patients with left-ventricular
dysfunction: the CAPRICORN randomised trial.  The Lancet
2001, 357:1385-1390.
16. The (PARAGON)-B Investigators: Randomized, Placebo-Con-
trolled Trial of Titrated Intravenous Lamifiban for Acute
Coronary Syndromes.  Circulation 2002, 105:316-321.
17. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seif-
ert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W,
Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H:
Randomized Trial of Tamoxifen Versus Tamoxifen Plus
Aminoglutethimide as Adjuvant Treatment in Postmeno-
pausal Breast Cancer Patients With Hormone Receptor-
Positive Disease: Austrian Breast and Colorectal Cancer
Study Group Trial 6.  J Clin Oncol 2003, 21:984-990.
18. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM,
Neumann FJ, Bollwein H, Volmer C, Gawas M, Berger PB, Schomig for
the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early
Action for Coronary Treatment (ISAR-REACT) Study Investigators:
A Clinical Trial of Abciximab in Elective Percutaneous Cor-
onary Intervention after Pretreatment with Clopidogrel.  N
Engl J Med 2004, 350:232-238.
19. Antman EM, The Magnesium in Coronaries (MAGIC) Trial Investiga-
tors: Early administration of intravenous magnesium to high-
risk patients with acute myocardial infarction in the Magne-
sium in Coronaries (MAGIC) Trial: a randomised controlled
trial.  The Lancet 2002, 360:1189-1196.
20. Australian and New Zealand Intensive Care Society (ANZICS) Clini-
cal Trials Group: Low-dose dopamine in patients with early
renal dysfunction: a placebo-controlled randomised trial.  The
Lancet 2000, 356:2139-2143.
21. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kis-
tler JP, Alber GW, Pettigrew LC, Adams HP, Jackson CM, Pullicino P,
for the Warfarin-Aspirin Recurrent Stroke Study Group: A Com-
parison of Warfarin and Aspirin for the Prevention of Recur-
rent Ischemic Stroke.  N Engl J Med 2001, 345:1444-1451.
22. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P,
Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M,
Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW:
A Calcium Antagonist vs a Non-Calcium Antagonist Hyper-
tension Treatment Strategy for Patients With Coronary
Artery Disease: The International Verapamil-Trandolapril
Study (INVEST): A Randomized Controlled Trial.  JAMA 2003,
290:2805-2816.
23. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki
R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R:
Additional file 1
RCTs identified as having extended use of interim analysis or extended 
recommendations made by DMCs, with potential to introduce bias. A list 
of trials identified as having reported extended use of interim analysis or 
recommendations by DMCs with the potential to introduce bias. Trials are 
sorted based on the interim trends observed or reason for interim analysis 
related recommendation. ^ CVD-Cardiovascular Disease, INF-Infection, 
OBGYN-Obstetrics and Gynecology, ONC-Oncology, NEURO-Neurol-
ogy. Information in brackets:. * R denotes a regulatory trial or that the 
intervention was investigational when the trial was completed and DMC 
denotes specification of a DMC in the trial publication. DMC specified in 
24/28 cases, R trials: 9/28 cases. ** TTE denotes time to event. *** Infor-
mation in brackets: TA denotes that treatment arm specific rate were ana-
lyzed during interim analysis, OA denotes that overall rates were analyzed 
during interim analysis, Masked denotes that masking of data was main-
tained during interim analysis (where specified/reported in the trial pub-
lication).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2288-8-12-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Research Methodology 2008, 8:12 http://www.biomedcentral.com/1471-2288/8/12
Page 8 of 8
(page number not for citation purposes)
Randomized Trial of Amifostine in Locally Advanced Non-
Small-Cell Lung Cancer Patients Receiving Chemotherapy
and Hyperfractionated Radiation: Radiation Therapy Oncol-
ogy Group Trial 98-01.  J Clin Oncol 2005, 23:2145-2154.
24. Shih WJ: Sample size re-estimation- journey for a decade.  Sta-
tistics in Medicine 2001, 20:515-518.
25. Senn S: 'Importance of trends in the interpretation of an over-
all odds ratio in the meta-analysis of clinical trials of clinical
trials' (letter).  Statistics in Medicine 1994, 13:293-295.
26. International Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH)
Steering Committee: ICH Tripartite Guidelines: General Con-
siderations for Clinical Trials (E8).  1997 [http://www.ich.org/
LOB/media/MEDIA484.pdf].
27. Scherer RW, Langenberg P, von Elm E: Full publication of results
initially presented in abstracts.  Cochrane Database of Methodology
Reviews 2005.
28. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG:
Empirical Evidence for Selective Reporting of Outcomes in
Randomized Trials: Comparison of Protocols to Published
Articles.  JAMA 2004, 291:2457-2465.
29. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Ber-
man L, Shi H, Buebendorf E, Topol EJ, for the CAMELOT Investiga-
tors: Effect of Antihypertensive Agents on Cardiovascular
Events in Patients With Coronary Disease and Normal
Blood Pressure: The CAMELOT Study: A Randomized Con-
trolled Trial.  JAMA 2004, 292:2217-2225.
30. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Far-
relly L, Kagason N, Zumla A, Gillespie SH: Co-trimoxazole as
prophylaxis against opportunistic infections in HIV-infected
Zambian children (CHAP): a double-blind randomised pla-
cebo-controlled trial.  The Lancet 2004, 364(9448):1865-1871.
31. SPORTIF Executive Steering Committee for the SPORTIF V Investi-
gators: Ximelagatran vs Warfarin for Stroke Prevention in
Patients With Nonvalvular Atrial Fibrillation: A Rand-
omized Trial.  JAMA 2005, 293:690-698.
32. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg
H, Karakas Tunca, Metzner B, Hossfeld DK, Bischoff HG, Franke A,
Reiser M, Muller P, Mantovani L, Grundeis M, Rothmann F, von Sey-
dewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K,
Kneba M, Baudis M, Schmitz N, Pfab R, Koppler H, Parwaresch R,
Pfreundschuh M, Havemann K: Randomized Study to Evaluate
the Use of High-Dose Therapy as Part of Primary Treatment
for "Aggressive" Lymphoma.  J Clin Oncol 2002, 20:4413-4419.
33. Kuppermann M, Varner RE, Summitt RL Jr, Learman LA, Ireland C,
Vittinghoff E, Stewart AL, Lin F, Richter HE, Showstack J, Hulley SB,
Washington AE: Effect of Hysterectomy vs Medical Treatment
on Health-Related Quality of Life and Sexual Functioning:
The Medicine or Surgery (Ms) Randomized Trial.  JAMA 2004,
291:1447-1455.
34. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V,
Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU:
Phase III Trial of Long-Term Adjuvant Androgen Depriva-
tion After Neoadjuvant Hormonal Cytoreduction and Radi-
otherapy in Locally Advanced Carcinoma of the Prostate:
The Radiation Therapy Oncology Group Protocol 92-02.  J
Clin Oncol 2003, 21:3972-3978.
35. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M,
Orgogozo JM, Whitehead J: Glycine antagonist (gavestinel) in
neuroprotection (GAIN International) in patients with acute
stroke: a randomised controlled trial.  The Lancet 2000,
355(9219):1949-1954.
36. Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JAH,
Hatton M, Johnson PWM, Martin WMC, Rankin EM, James LE, Gre-
gory WM, Qian W, Lee SM: Gemcitabine Plus Carboplatin Ver-
sus Mitomycin, Ifosfamide, and Cisplatin in Patients With
Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III
Randomized Study of the London Lung Cancer Group.  J Clin
Oncol 2005, 23:142-153.
37. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE,
Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP: Whole
brain radiation therapy with or without stereotactic radio-
surgery boost for patients with one to three brain metas-
tases: phase III results of the RTOG 9508 randomised trial.
The Lancet 2004, 363(9422):1665-1672.
38. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P,
Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H: ACVBP versus
CHOP plus Radiotherapy for Localized Aggressive Lym-
phoma.  N Engl J Med 2005, 352:1197-1205.
39. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AAJ,
Arntz HR, Arntz HR, Bogaerts K, Danays T, Lindahl B, Makijarvi M,
Verheugt F, Van de Werf F: Efficacy and Safety of Tenecteplase
in Combination With the Low-Molecular-Weight Heparin
Enoxaparin or Unfractionated Heparin in the Prehospital
Setting: The Assessment of the Safety and Efficacy of a New
Thrombolytic Regimen (ASSENT)-3 PLUS Randomized
Trial in Acute Myocardial Infarction.  Circulation 2003,
108:135-142.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2288/8/12/prepub